Format

Send to

Choose Destination
Ann Pharmacother. 2002 Mar;36(3):512-6.

Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.

Author information

1
College of Pharmacy & Allied Health Professions, Wayne State University, Detroit, MI, USA. jdougher@dmc.org

Abstract

OBJECTIVE:

To evaluate the role of risedronate in corticosteroid-induced osteoporosis.

DATA SOURCES:

Clinical literature was accessed through MEDLINE (1966-February 2001). Key search terms included risedronate, corticosteroid, osteoporosis, and bisphosphonate.

DATA SYNTHESIS:

Corticosteroid-induced osteoporosis (CIO) is clinically challenging and can lead to fractures. Risedronate, an oral bisphosphonate, has been studied for use in CIO. Trials focusing on the use of risedronate in these patients were reviewed.

CONCLUSIONS:

Risedronate 5 mg/d increased bone mineral density at lumbar, femoral neck, and trochanter skeletal sites in patients recently initiated on or receiving long-term corticosteroid therapy. Further investigation is needed to determine risedronate's effects on fracture prevention. The drug was well tolerated.

PMID:
11895066
DOI:
10.1345/aph.1A114
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center